Vivacelle Bio careers

The company is commercializing. Vivacelle, a phospholipid nanoparticle formulation designed for the treatment of hypovolemia due to severe blood loss or infection. Vivacelle is as potent as blood. But it does not have the toxicity of blood. Previous products have failed due to toxicity. Vivacelle has not shown any toxicity. It was designed by using only components that are well established to be safe. Numerous patents have been issued (patentbuddy.com/Inventor/Simpkins-Cuthbert-O/11587742). The addressable market is 13 billion dollars. The management team is experienced. The Company is raising funds to do GMP manufacturing and fulfill the FDA request for more product manufacturing quality control information. An exit is planned for 2019-2020. This is a disruptive technology that will dramatically change the approach to many disease states. There is pipeline of multiple products.